Last reviewed · How we verify

NCT01503866

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

Completed Phase 1 Last updated 29 May 2025
What this trial tests

Phase 1 trial testing bardoxolone methyl in Healthy in 6 participants. Completed in 31 December 2011.

Timeline
1 December 2011
Primary endpoint
31 December 2011
31 December 2011

Quick facts

Lead sponsorBiogen
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment6
Start date1 December 2011
Primary completion31 December 2011
Estimated completion31 December 2011
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Biogen — full company profile →

Who can join

Adults 18 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the absorption and excretion kinetics of bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and feces in men following a single oral does or 20 mg of \[14C\]-bardoxolone methyl.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
    Wang YY, Yang YX, Zhe H, He ZX, et al · · 2014 · cited 187× · PMID 25364233 · DOI 10.2147/dddt.s68872

Verify or expand the search:

Other trials of bardoxolone methyl

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Biogen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01503866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing